Immunome (IMNM) Net Income towards Common Stockholders (2019 - 2026)
Immunome (IMNM) posted Net Income towards Common Stockholders of -$244.2 million for Q1 2026, down 234.11% on a QoQ basis from -$73.1 million in Q4 2025, and down 443.98% year-over-year from $71.0 million in Q1 2025.
Immunome (IMNM) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Immunome's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$244.2 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 443.98% year-over-year to -$244.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$489.6 million (down 48.11% YoY) and the FY2025 annual result came in at -$404.8 million, up 1.88% from the prior year.
- Net Income towards Common Stockholders was -$244.2 million for Q1 2026 at Immunome, down from -$73.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$4.3 million in Q3 2023 and bottomed at -$244.2 million in Q1 2026.
- A 5-year average of -$65.3 million and a median of -$70.3 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders slumped 2796.5% — and 2025, when it surged 66.09%.
- Immunome's Net Income towards Common Stockholders stood at -$7.8 million in 2022, then plunged by 1089.75% to -$92.6 million in 2023, then advanced by 10.11% to -$83.3 million in 2024, then climbed by 12.21% to -$73.1 million in 2025, then sank by 234.11% to -$244.2 million in 2026.
- Business Quant data shows IMNM's Net Income towards Common Stockholders at -$244.2 million in Q1 2026, -$73.1 million in Q4 2025, and -$101.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -0.68 |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Immunome | 2.60 Bn | 2.02 Bn | - | -244.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -244.25 Mn |
| Dec 31, 2025 | -73.10 Mn |
| Sep 30, 2025 | -101.90 Mn |
| Jun 30, 2025 | -70.30 Mn |
| Mar 31, 2025 | -44.90 Mn |
| Dec 31, 2024 | -83.27 Mn |
| Sep 30, 2024 | -116.13 Mn |
| Jun 30, 2024 | -86.23 Mn |
| Mar 31, 2024 | -132.40 Mn |
| Dec 31, 2023 | -92.63 Mn |
| Sep 30, 2023 | -4.35 Mn |
| Jun 30, 2023 | -16.07 Mn |
| Mar 31, 2023 | -4.57 Mn |
| Dec 31, 2022 | -7.79 Mn |
| Sep 30, 2022 | -9.16 Mn |
| Jun 30, 2022 | -10.73 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -7.85 Mn |
| Sep 30, 2021 | -7.72 Mn |
| Jun 30, 2021 | -26.04 Mn |